

Product Data Sheet

Product Name: PRO-6E

Cat. No.: GC73881

Chemical Properties

Cas. No. 2353493-69-1


Formula $C_{42}H_{44}Cl_2FN_7O_7$ M.Wt 848.75

Solubility DMSO : ≥ 100 mg/mL (117.82 mM) Storage -20°C

General tips For obtaining a higher solubility , please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

PRO-6E is an oral active PROTAC based on Cereblon ligand, and induces the degradation of MET with maximum degradation of 81.9% at $1\text{ }\mu\text{M}$ in MKN-45 cells. PRO-6E inhibits tumor growth in vivo and in vitro. PRO-6E induces cell apoptosis and induces cell arrest (Structure Note: (Blue: Cereblon ligand , Black: linker ; Pink: ALK/c-Met inhibitor Crizotinib)).

PRO-6E (0.03 - $10\text{ }\mu\text{M}$; 48 h) inhibits the cell growth in MKN-45, SNU-638 cells[1]. PRO-6 E ($1\text{ }\mu\text{M}$; over 24 h) facilitates MET degradation in MKN-45 cells[1]. PRO-6 E (0.1 - $1\text{ }\mu\text{M}$; 48 h) increase in the percentage of G2/M phase cells and decrease in the percentage of S phase cells in MKN-45 cells[1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

PRO-6E (oral gavage; 30 mg/kg/day for 15 days) inhibits tumor growth in MKN-45 cell-derived xenograft tumor model[1].

References:

[1]. Chen JJ, et al. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation. Cancer Sci. 2023;114(5):1958-1971.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA